Abstract
Corcoran and Chabner (Nov. 1 issue)1 elegantly describe the use of circulating tumor DNA (ctDNA) analysis in patients with cancer. However, one issue that was not adequately discussed is early detection. We recently analyzed the tumor size, amount of ctDNA in a 10-ml blood sample, fraction of ctDNA in overall cell-free DNA (cfDNA), number of retrieved genomes, and likelihood of tumor detection with ctDNA analysis. We concluded that, in general, this form of technology is unlikely to detect tumors that are smaller than 10 mm in diameter,2 primarily because no retrieval of ctDNA from the circulation in patients with early disease leads to sampling error. Our calculations are supported by recent data showing poor sensitivity (10%) of ctDNA analysis in detecting breast cancer in asymptomatic persons in whom breast cancer has been detected by means of screening mammography.3 Although this new cancer biomarker has exciting potential for many clinical applications, its use for early detection and population screening should be approached with caution.